Effect Of Intravenous Tranexamic Acid Research Articles

A systematic review of the effectiveness of intravenous tranexamic acid administration in managing perioperative blood loss in patients undergoing spine surgery.

This systematic review aimed to identify the effectiveness of intravenous tranexamic acid (TXA) administration in managing perioperative blood loss in patients undergoing spine surgery. The study design was a systematic review and meta-analysis. Quantitative articles were pooled in a statistical meta-analysis using the Joanna Briggs Institute Meta-Analysis of Statistical Assessment and Review Instrument. Twelve studies totaling 934 participants carried out between 1960 and 2013 were included in the review. Intraoperative blood loss showed statistically significant (P<.0001) blood loss in the control group compared with that in the treatment group. Perioperative blood loss was approaching significance for blood loss in the control group with an overall P=.067. TXA helps reduce perioperative blood loss for patients undergoing spine surgery. TXA should be administered to patients undergoing spine surgery when significant blood loss is anticipated.

Comparison effect of intravenous tranexamic acid and misoprostol for postpartum haemorrhage.

Background:Postpartum haemorrhage (PPH) is the third-most common cause of maternal death in the United States and it is still the first prevalent cause of maternal death in developing countries. Active prevention of haemorrhage with an uterotonic or other new drugs leads to a decrease in postpartum vaginal haemorrhage. The aim of this study was to compare anti-haemorrhagic effect of Tranexamic acid (TXA) and Misoprostol for PPH.Patients and Methods:In a double-blinded randomised control clinical trial, 200 women were included after Caesarean or natural vaginal delivery with abnormal PPH. They were divided into two equal intervention and control groups. Effect of intravenous TXA and Misoprostol for postpartum haemorrhage was examined.Results:The mean age of patients was 26.7 ± 6.5 years which ranged from 14 to 43 years. The sonographic gestational age in the group treated with TXA was 37.7 ± 3.4 weeks and it was 37.4 ± 3.3 weeks for the other group (P = 0.44). The haemorrhage in the TXA and Misoprostol groups was 1.2 ± 0.33 litres and 1.18 ± 0.47 litres, respectively (P = 0.79). The haemoglobin levels after 6-12 hours of labour, in TXA group was more than that of the Misoprostol group, but this difference was not statistically significant (P = 0.22 and P = 0.21, respectively).Conclusion:Regarding to the superior results in Misoprostol group in one hand and lack of significant differences between two groups in haemorrhage during labour, post-partum haemoglobin level and discharge haemoglobin level, we can state that Misoprostol has no specific preferences to TXA, but more studies with greater population are needed.

Effectiveness of intravenous tranexamic acid (TXA) administration in managing perioperative blood loss in patients undergoing spine surgery: a systematic review

Effectiveness of intravenous tranexamic acid (TXA) administration in managing perioperative blood loss in patients undergoing spine surgery: a systematic review

Effectiveness of intravenous Tranexamic Acid (TXA) administration in managing perioperative blood loss in patients undergoing spine surgery: a systematic review protocol

Effectiveness of intravenous Tranexamic Acid (TXA) administration in managing perioperative blood loss in patients undergoing spine surgery: a systematic review protocol

Effect of Intravenous Tranexamic Acid Administration on Blood Loss During and After Cesarean Delivery

Abstract Objective To assess the effect of intravenous tranexamic acid on blood loss during and after cesarean delivery. Methods One hundred pregnant women were randomized to receive either 10 mg/kg of tranexamic acid or placebo intravenously 20 minutes before incision in a double-blind controlled study. Postplacental delivery blood loss, postoperative hemorrhage 2 hours after surgery, and oxytocin administration were recorded. Results The patients’ mean age, weight, and duration of surgery were similar between the 2 groups. Mean blood loss was significantly less in the tranexamic acid group compared with the control group for both intraoperative bleeding (262.5 ± 39.6 vs 404.7 ± 94.4 mL) and postoperative bleeding (67.1 ± 6.5 vs 141.0 ± 33.9 mL; P Conclusion Intravenous tranexamic acid decreased intra- and postoperative blood loss and oxytocin administered in patients delivered by cesarean.

The effect of intravenous tranexamic acid on blood loss and surgical field quality during endoscopic sinus surgery: a placebo-controlled clinical trial

Study Objectives To evaluate the effects of intravenous (IV) tranexamic acid on blood loss and surgical field quality during functional endoscopic sinus surgery (FESS). Design Randomized, double-blinded, controlled trial. Setting Operating room and postoperative recovery area of a university-affiliated hospital. Patients 84 consecutive, adult, ASA physical status 1 and 2 patients undergoing FESS. Interventions Patients were randomized to receive either IV tranexamic acid 10 mg/kg (TA group) or sterile water 0.1 mL/kg (placebo group) as a bolus dose immediately after induction of anesthesia. Measurements Amount of blood loss and bleeding and satisfaction scores were obtained from the surgeon. Main Results Blood loss in the TA group was 184 ± 64 mL and in the placebo group, 312 ± 75 mL on average ( P < 0.01). The median (range) bleeding score in the TA group was significantly lower than the placebo group [2 (1-3) vs 2.5 (2-4); P < 0.0001]. The surgeon was more satisfied with the surgical field in the TA group than the placebo group [median score: 4 (3-5) vs 3 (1-5), P < 0.001]. Conclusion Intravenous tranexamic acid effectively reduces bleeding and improves the surgical field during FESS.

Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery

Objective To assess the effect of intravenous tranexamic acid on blood loss during and after cesarean delivery. Methods One hundred pregnant women were randomized to receive either 10 mg/kg of tranexamic acid or placebo intravenously 20 minutes before incision in a double-blind controlled study. Postplacental delivery blood loss, postoperative hemorrhage 2 hours after surgery, and oxytocin administration were recorded. Results The patients’ mean age, weight, and duration of surgery were similar between the 2 groups. Mean blood loss was significantly less in the tranexamic acid group compared with the control group for both intraoperative bleeding (262.5 ± 39.6 vs 404.7 ± 94.4 mL) and postoperative bleeding (67.1 ± 6.5 vs 141.0 ± 33.9 mL; P < 0.001), respectively. Oxytocin administration was significantly less in the tranexamic acid group compared with the control group (39 ± 5.8 vs 43 ± 5.4 units; P = 0.001). Conclusion Intravenous tranexamic acid decreased intra- and postoperative blood loss and oxytocin administered in patients delivered by cesarean.

Tranexamic acid does not correct the haemostatic impairment caused by hydroxyethyl starch (200 kDa/0.5) after cardiac surgery

We investigated the effect of intravenous tranexamic acid on hydroxyethyl starch (HES)-induced clot strength impairment after cardiac surgery. Patients were randomized to receive either 1 g tranexamic acid or the same volume of 0.9% saline after administration of 15 ml/kg of 6% HES (molecular weight, 200 kDa; degree of substitution, 0.5) in the immediate postoperative period. Modified thromboelastometry (ROTEM) using different activators [intrinsic ROTEM (InTEM), extrinsic ROTEM (ExTEM), fibrinogen ROTEM (FibTEM)] was carried out to evaluate clot formation and lysis. The clot formation time was prolonged, and the maximum clot firmness (MCF) and shear elastic modulus [G = 5000 x MCF / (100-MCF), dynes/cm(2)] decreased (all activators of ROTEM) after completion of HES (P < 0.001, two-factor analysis of variance). These abnormalities in blood coagulation persisted despite tranexamic acid. Maximal lysis (FibTEM), indicative of fibrinolytic activity, was increased after HES but no effect of tranexamic acid was observed. The cumulative chest tube drainage until the first postoperative morning was not different between the groups (1008 +/- 251 and 1081 +/- 654 ml, P = 0.698, respectively). We conclude that after cardiopulmonary bypass, HES-induced impairment in clot formation and strength, or increased fibrinolytic capacity, is not reversed by the administration of tranexamic acid.